Supernus Pharmaceuticals SUPN Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's accrued expenses?
- Supernus Pharmaceuticals (SUPN) reported accrued expenses of $24.21M in Q1 2026.
- How has Supernus Pharmaceuticals's accrued expenses changed year-over-year?
- Supernus Pharmaceuticals's accrued expenses increased by 37.6% year-over-year, from $17.6M to $24.21M.
- What is the long-term trend for Supernus Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's accrued expenses has grown at a 26.5% compound annual growth rate (CAGR), from $9.08M to $29.45M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.